Galectin-3: A biochemical marker to detect paroxysmal atrial fibrillation?

Yusuf Selcoki, H İbrahim Aydin, Tugrul H Celik, Ahmet Isleyen, Ali Erayman, M Bora Demircelik, Hilmi Demirin, Aydin Kosus, Beyhan Eryonucu


Purpose: Atrial fibrillation (AF) is the most common form of arrhythmia. AF leads to electrical remodelling and fibrosis of the atria; however, the mechanism(s) remain poorly understood. Galectin-3 is a potential mediator of cardiac fibrosis. The present study aimed to examine the relationship between serum galectin-3 levels and paroxysmal AF.

Methods: Forty-six patients with paroxysmal AF and preserved left ventricular systolic function, and 38 age- and gender-matched control subjects, were involved in the study. Serum galectin-3 levels were analyzed with an enzyme-linked immunosorbent assay (ELISA).

Results: Serum galectin-3 levels (median 1.38 ng/mL; 1.21 ng/mL-1.87 ng/mL; p< 0.001) were significantly elevated in patients with paroxysmal AF compared with the control. Left atrial diameter was significantly higher in patients with paroxysmal AF (41.2±3.0 mm vs. 39.6±3.3 mm). Left atrial diameter was found to be significantly correlated with serum galectin-3 levels in patients with paroxysmal AF (r= 0.378, p= 0.001).

Conclusion: Serum galectin-3 levels are significantly elevated and significantly correlated with left atrial diameter in patients with paroxysmal AF.

Full Text:




  • There are currently no refbacks.

Comments on this article

View all comments

© 2007-2018 Canadian Society for Clinical Investigation.
C.I.M. provides open access to all of its content 6 months after the date of publication